美国食品药品监督管理局（FDA）已正式授予纳武利尤单抗（Nivolumab）传统批准，该药物适用于曾接受自体造血干细胞移植（HSCT）及维布妥昔单抗（Brentuximab Vedotin）治疗后，病情出现复发或难治性的经典霍奇金淋巴瘤（cHL）成年患者。
此次传统批准的授予，标志着该免疫疗法在治疗这一特定患者群体方面获得了监管机构的全面认可。纳武利尤单抗由施贵宝（Bristol-Myers Squibb）研发，是一种PD-1抑制剂，能够通过激活人体自身的免疫系统来攻击癌细胞。
这一决定为患有复发或难治性经典霍奇金淋巴瘤的成人提供了新的重要治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.